T 1462/24 (Dimethyl fumarate or Monomethyl fumarate for treatment of multiple sclerosis/ BIOGEN| |) of 26.11.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T146224.20251126
- Date of decision
- 26 November 2025
- Case number
- T 1462/24
- Online on
- 20 April 2026
- Petition for review of
- -
- Application number
- 13169139.6
- IPC class
- G01N 33/50G01N 33/68
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions and uses for treating Multiple Sclerosis
- Applicant name
- Biogen MA Inc.
- Opponent name
- neuraxpharm Arzneimittel GmbH
Generics [UK] Limited (trading as Mylan)
Polpharma S.A.
Hexal AG
Zentiva k.s.
G. L. Pharma GmbH
Stada-Arzneimittel Aktiengesellschaft
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Adalvo Ltd.
Accord Healthcare Ltd
Glenmark Pharmaceuticals Europe Ltd
Kraus & Lederer PartGmbB
BIOGARAN
Dr. Schön, Neymeyr & Partner Patentanwälte mbB
betapharm Arzneimittel GmbH - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 76(1)European Patent Convention Art 112(1)(a)European Patent Convention R 106Rules of procedure of the Boards of Appeal 2020 Art 016(1)
- Keywords
- Amendments - allowable (no)
Referral to the Enlarged Board of Appeal - (no)
Objections under Rule 106 EPC - rejected
Apportionment of costs - (yes) - Catchword
- -
- Cited cases
- G 0002/10R 0004/08R 0014/11R 0006/22R 0021/22T 0012/81T 0401/94T 0615/95T 0783/09T 1261/21T 1441/21
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The objections under Rule 106 EPC are rejected.
3. The patent is revoked.
4. The patent proprietor shall bear the costs for remuneration of one day for at most two professional representatives present at the oral proceedings of 26 November 2025 for each opponent.